Protara Therapeutics Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Jesse Shefferman
Chief executive officer
US$1.9m
Total compensation
| CEO salary percentage | 31.9% |
| CEO tenure | 5yrs |
| CEO ownership | 4.0% |
| Management average tenure | 3yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst
Dec 10Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
Nov 22
Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?
Aug 08Protara: A Bombed Out Biotech With A Very Positive Skew
Feb 22Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
Dec 16We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth
Apr 22The Prognosis For Protara Therapeutics
Oct 13Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
Sep 12Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?
Mar 21Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?
Dec 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$42m |
| Jun 30 2024 | n/a | n/a | -US$41m |
| Mar 31 2024 | n/a | n/a | -US$42m |
| Dec 31 2023 | US$2m | US$608k | -US$40m |
| Sep 30 2023 | n/a | n/a | -US$69m |
| Jun 30 2023 | n/a | n/a | -US$67m |
| Mar 31 2023 | n/a | n/a | -US$64m |
| Dec 31 2022 | US$3m | US$588k | -US$66m |
| Sep 30 2022 | n/a | n/a | -US$37m |
| Jun 30 2022 | n/a | n/a | -US$40m |
| Mar 31 2022 | n/a | n/a | -US$45m |
| Dec 31 2021 | US$4m | US$570k | -US$47m |
| Sep 30 2021 | n/a | n/a | -US$46m |
| Jun 30 2021 | n/a | n/a | -US$43m |
| Mar 31 2021 | n/a | n/a | -US$37m |
| Dec 31 2020 | US$8m | US$507k | -US$34m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$22m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$379k | US$344k | -US$8m |
| Sep 30 2019 | n/a | n/a | -US$7m |
| Dec 31 2018 | US$301k | US$268k | -US$4m |
Compensation vs Market: Jesse's total compensation ($USD1.91M) is above average for companies of similar size in the US market ($USD642.68K).
Compensation vs Earnings: Jesse's compensation has been consistent with company performance over the past year.
CEO
Jesse Shefferman (52 yo)
5yrs
Tenure
US$1,906,132
Compensation
Mr. Jesse Shefferman serves as Chief Executive Officer, President and Director of Protara Therapeutics, Inc. (Formerly known as Proteon Therapeutics Inc.) since January 2020. He Co-founded Protara Therapeu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-founder | 5yrs | US$1.91m | 4.01% $ 5.1m | |
| Co-Founder | 4yrs | US$1.04m | 0.31% $ 388.9k | |
| Chief Financial Officer | 2yrs | US$1.44m | 0% $ 0 | |
| VP, Principal Accounting Officer & Controller | 2.5yrs | no data | 0.083% $ 104.6k | |
| Senior Vice President of Investor Relations & Corporate Affairs | 3yrs | no data | no data | |
| General Counsel & Corporate Secretary | 3yrs | no data | no data |
3.0yrs
Average Tenure
47.5yo
Average Age
Experienced Management: TARA's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-founder | 5yrs | US$1.91m | 4.01% $ 5.1m | |
| Independent Chairman of the Board | 6.3yrs | US$192.26k | 0.15% $ 184.2k | |
| Independent Director | 5yrs | US$118.26k | 0.15% $ 190.3k | |
| Independent Director | 5yrs | US$75.76k | 0% $ 0 | |
| Independent Director | 5yrs | US$71.76k | 0% $ 0 | |
| Independent Director | 5yrs | US$91.76k | 0% $ 0 | |
| Independent Director | 4yrs | US$72.76k | 0% $ 0 | |
| Independent Director | 4.5yrs | US$66.76k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$85.76k | 0% $ 0 |
5.0yrs
Average Tenure
58yo
Average Age
Experienced Board: TARA's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 06:48 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Protara Therapeutics, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Schmidt | Guggenheim Securities, LLC |
| Etzer Darout | Guggenheim Securities, LLC |
| Andrew Fein | H.C. Wainwright & Co. |